EVALUATING THE COST-EFFECTIVENESS OF THE ADDITION OF RITUXIMAB TO CHEMOTHERAPY IN THE FIRST LINE TREATMENT OF FOLLICULAR LYMPHOMA PATIENTS IN THE UK

被引：0
|
作者：
Rafia, R. [1 ]
Papaioannou, D. [1 ]
Stevenson, M. [1 ]
Rathbone, J. [1 ]
Woods, H. B. [1 ]
机构：
[1] Univ Sheffield, Sheffield, S Yorkshire, England
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.1165
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A445 / A445
页数：1
相关论文
共 50 条
  • [21] Impact onMedical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare
    Griffiths, Robert I.
    Gleeson, Michelle L.
    Mikhael, Joseph
    Danese, Mark D.
    JOURNAL OF CANCER EPIDEMIOLOGY, 2012, 2012
  • [22] Cost-effectiveness analysis of treatment regimens with obinutuzumab plus chemotherapy in Japan for untreated follicular lymphoma patients
    Ohno, Shinya
    Shoji, Ayako
    Hatake, Kiyohiko
    Oya, Naoko
    Igarashi, Ataru
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (10) : 1130 - 1141
  • [23] Cost-Effectiveness of Rituximab As Maintenance Treatment for Relapsed Follicular Lymphoma: Results of a Population Based Study
    Blommestein, Hedwig M.
    Issa, Djamila E.
    Pompen, Marjolein
    Revil, Cedric
    Hoogendoorn, Mels
    Joosten, Peter
    Zweegman, Sonja
    Huijgens, Peter C.
    Uyl-de Groot, Carin A.
    BLOOD, 2012, 120 (21)
  • [24] THE COST EFFECTIVENESS OF RITUXIMAB MAINTENANCE THERAPY IN PATIENTS WITH FOLLICULAR LYMPHOMA
    Mervin, M. C.
    VALUE IN HEALTH, 2016, 19 (03) : A153 - A153
  • [25] Follicular Lymphoma: First-Line Treatment Without Chemotherapy for Follicular Lymphoma
    Reagan, Patrick M.
    Friedberg, Jonathan W.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2015, 16 (07)
  • [26] Follicular Lymphoma: First-Line Treatment Without Chemotherapy for Follicular Lymphoma
    Patrick M. Reagan
    Jonathan W. Friedberg
    Current Treatment Options in Oncology, 2015, 16
  • [27] Fludarabine, Cyclophosphamide and Rituximab As First Line Treatment In Follicular Lymphoma
    Vicente, Fatima de la Cruz
    Cruz, Estrella Carrillo
    Rodriguez, Maria Sole
    Niebla, Ana Marin
    Herranz, Eduardo Rios
    Galiana, Maria Luz Martino
    Gonzalez, Jose Falantes
    Cuadrado, Isabel Montero
    Campos, Jose Gonzalez
    Tocino, Ildefonso Espigado
    Perez-Simon, Jose A.
    BLOOD, 2013, 122 (21)
  • [28] Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma
    Spencer, Scott J.
    Guzauskas, Gregory F.
    FeLizzi, Federico
    Launonen, Aino
    Dawson, Keith
    Veenstra, David L.
    Masaquel, Anthony
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (05): : 615 - 624
  • [29] Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view
    Thielen, Frederick W.
    Kersten, Marie-Jose
    Kuizenga, Pim
    Hoogendoorn, Mels
    Posthuma, Eduardus F. M.
    Stevens, Wendy B. C.
    Uyl-de Groot, Carin A.
    Blommestein, Hedwig M.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (12) : 1411 - 1422
  • [30] Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study
    Blommestein, Hedwig M.
    Issa, Djamila E.
    Pompen, Marjolein
    Ten Hoor, Gerhard
    Hogendoorn, Mels
    Joosten, Peter
    Zweegman, Sonja
    Huijgens, Peter C.
    Uyl-de Groot, Carin A.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 92 (05) : 398 - 406
12345